Roman M.
- Country
- Czechia
- Department
- Department of Internal Medicine
Research Overview
- Phase 3 Study of KAI-9531 in Adults With Obesity or Overweight With Weight-Related Comorbidities Without Diabetes
- Efficacy and Safety Evaluation of BAY 3018250 in Symptomatic Proximal Deep Vein Thrombosis: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial
- Phase 3 Randomized Study Comparing Asundexian and Apixaban for Stroke Prevention in Atrial Fibrillation Patients at Risk
Data & Insights
Has run more than one trial at 726 of 1462 partner sites.
Specializations
Inflammatory Bowel Disease
Clinical research in Crohn’s disease and ulcerative colitis, with interest in both active disease control and longer-term maintenance of remission. The portfolio includes studies in moderate to severe disease, as well as treatment-resistant and refractory forms of inflammatory bowel disease.
- Moderately to severely active Crohn’s disease
- Moderately to severely active ulcerative colitis
- Maintenance of clinical remission
- Endoscopic response and mucosal healing
Research activity also extends to broader gastrointestinal inflammation, including combined Crohn’s disease and ulcerative colitis programs and therapies aimed at improving bowel symptoms and intestinal disease control.
Cardiovascular Disease and Heart Failure
Clinical trial involvement centers on cardiovascular disease, especially prevention of major adverse events, atherosclerotic cardiovascular disease, and management of heart failure across reduced, mildly reduced, and preserved ejection fraction phenotypes.
- Acute and chronic heart failure
- Heart failure with reduced ejection fraction
- Heart failure with preserved or mildly reduced ejection fraction
- Cardiovascular event prevention
Additional interests include acute heart failure, hypertension, and cardiovascular risk reduction in patients with established disease or multiple cardiometabolic risk factors.
Atrial Fibrillation, Stroke, and Thromboembolism
Research activity includes prevention of stroke and systemic embolism in atrial fibrillation, as well as treatment strategies for acute ischemic cerebrovascular disease and venous thrombotic conditions.
- Atrial fibrillation-related stroke prevention
- Acute ischemic stroke and high-risk transient ischemic attack
- Proximal deep vein thrombosis
- Thrombolysis and antithrombotic care
This area also includes patients at elevated risk of recurrent cardioembolic and thrombotic events.
Metabolic and Lipid-Related Cardiovascular Risk
Clinical studies cover obesity, overweight, type 2 diabetes, and lipid-driven cardiovascular risk, with attention to patients who have established disease or high baseline risk.
- Elevated lipoprotein(a)
- Obesity-associated cardiovascular disease
- Type 2 diabetes with cardiovascular comorbidity
- High cardiovascular risk without prior infarction or stroke
Therapeutic interest also extends to cardiometabolic inflammation and prevention of first or recurrent major cardiovascular events.
Immune-Mediated and Gastrointestinal Comorbidity
The investigator is also involved in trials addressing immune-driven digestive disorders, including celiac disease and other immune system diseases affecting the gastrointestinal tract.
- Non-responsive celiac disease
- Gluten-related intestinal mucosal injury
- Immune-mediated intestinal inflammation
- Erosive esophagitis due to GERD
These studies broaden the therapeutic focus beyond IBD to include additional inflammatory and mucosal disorders of the digestive system.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.